©2024 Stanford Medicine
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
Not Recruiting
Trial ID: NCT02247804
Purpose
This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.
Official Title
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension
Stanford Investigator(s)
Ann Caroline Fisher, MD
Clinical Associate Professor, Ophthalmology
Eligibility
Inclusion Criteria:
-Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes require IOP-lowering treatment.
Exclusion Criteria:
* Previous enrollment in another Allergan Bimatoprost SR Study.
* Eye surgery (including cataract surgery) and/or any eye laser surgery within the past 6 months in the study eye
* Anticipated need for laser eye surgery in either eye within the first 52 weeks of the study duration
* History of glaucoma surgery
Intervention(s):
drug: Timolol Vehicle (placebo)
drug: Bimatoprost SR
drug: Active Comparator: Timolol 0.5%
other: Sham: Applicator Without Needle
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kristina Liu
(408) 726-5119